Study of Nexviazyme in children with infantile Pompe disease
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests the safety and effects of the enzyme replacement therapy avalglucosidase alfa (Nexviazyme) in children with infantile-onset Pompe disease. It is for children who have had Pompe symptoms since infancy and heart problems at diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be under 18 years old.
- Pompe symptoms started before 12 months of age.
- Heart muscle problems (cardiomyopathy) were present at diagnosis.
- Your child can have received either Myozyme/Lumizyme or Nexviazyme before, but not other Pompe treatments.
- If your child has had a different enzyme therapy (not Myozyme, Lumizyme, or Nexviazyme), they cannot join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if getting enzyme replacement therapy every 4 weeks instead of every 2 weeks is safe and effective for stable adults with late-onset Pompe disease. It may reduce the burden of frequent infusions.
This trial tests whether a higher dose of the enzyme medicine used for Pompe disease is safe and helpful. You may qualify if you already have Pompe disease and are currently receiving regular enzyme replacement therapy.
This trial is a registry, meaning it collects health information from people with confirmed Pompe disease. It may help researchers better understand the disease and improve future treatments.
This early-stage trial tests a new gene therapy for adults with late-onset Pompe disease who have already tried enzyme replacement therapy (ERT). The goal is to see if the gene therapy is safe and can help improve muscle strength and breathing.
This trial tests how well a new enzyme treatment (cipaglucosidase alfa with miglustat) works and how safe it is in children and babies with infant-onset Pompe disease. It may help by improving muscle function after earlier treatment or, for some babies, starting treatment when no prior enzyme therapy has been given.
This study tests a one-time gene therapy (AB-1009) for adults with late-onset Pompe disease. It aims to see if the treatment is safe and improves muscle and breathing function.
Hear when a new Glycogen Storage Disease Type II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.